This month on Synapse
UK life sciences prospects post-Brexit
Paul England discusses what recent events tell us about the intended role of the life sciences sector in the post-Brexit economy.
Topical issues
The CMA expands its focus to drug pricing
Competition law authorities hate the idea of getting involved in price determinations and, as a result, excessive pricing cases have suffered from middle-child syndrome for decades. However, it looks like things are about to change.
Data and market exclusivity in pharmaceuticals
In Taylor Wessing's latest webinar, Paul England, Manja Epping and Edward Vickers discuss the current scope and application of regulatory data protection and related market exclusivity rights being attached to certain pharmaceutical products.
The UK backs the UPC and Unitary Patent
Paul England explains the recent decision by the UK Government to ratify the agreement on a Unified Patents Court and Unitary Patent.
News
The Enlarged Board of Appeal rules on partial priority in G1/15
Integrase inhibitor patent invalid for lack of technical contribution
Court of Appeal upholds decision on construction of numerical ranges
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
